Merck & Company, Inc. vs Arcus Biosciences, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
RCUS
Arcus Biosciences, Inc.
$25.68
▲ 0.71%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.7/10

Q·Score Breakdown

6.7
Neutral
Overall
5.7
Neutral
6.2
Quality
0.2
7
Health
9.2
6.2
Growth
7.7
7.2
Valuation
5.7
7.1
Sentiment
7.2
MRK

Forward P/E of 11.5× is low relative to sector peers.

RCUS

Clean balance sheet with low leverage (0.3× debt-to-equity).

currently unprofitable (-143% margin).

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $34.00 (+32.4%)
10 analysts

Fundamentals

MRK
RCUS
31.5×
Trailing P/E
11.5×
Forward P/E
-7.3×
13.6%
Profit Margin
-142.9%
76.6%
Gross Margin
-111.7%
ROE
-63.3%
4.9%
Revenue Growth
26.9%
Earnings Growth
0.28
Beta
0.86
Price / Book
$277.0B
Market Cap
$3.2B
$73 – $125
52-Week Range
$7 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →